Diligence memo · auto-generated · as of July 2, 2026
Ovid Therapeutics Inc.
Ovid Therapeutics Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Ovid Therapeutics Inc. operates in Pharma, based in New York.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ovid Therapeutics Inc. has raised $106M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $75M on 2015-08-10.
Most recent recorded round closed around 2017-01-06.
Valuation (modeled)modeled
Provath models Ovid Therapeutics Inc. at approximately $907M (range $84M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.57× the median modeled value of Series C Pharma companies in 2016–2018 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 9.5 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 91% of Pharma peers (310 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Prevail Therapeutics Inc., Celsius Therapeutics, Inc., Akero Therapeutics, Inc., Advanced Cardiac Therapeutics Inc.
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.